Paula Vanderpluym's smartwatch may look like a small part of her wardrobe, but to a team of researchers in Toronto, it ...
In heart failure, the heart can no longer supply the body with enough blood. The condition often develops over many years, ...
Amarin Corporation plc (NASDAQ: AMRN) ("Amarin"), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today highlighted the important scientific and educational ...
Enrollment occurred across two Dallas hospitals; exclusions included transplant, LVAD, inotropes at discharge, existing meal ...
A new pill called baxdrostat is showing strong results in lowering dangerously high blood pressure in people who don’t ...
Initiated pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditis and surpassed 50% patient enrollment, with full enrollment expected in Q2 2026.Reported positive Phase II ARCHER data ...
AB-1002 is an investigational one-time gene therapy administered directly to the heart to promote production of a modified version (I-1c) of the naturally occurring protein inhibitor-1, designed to ...
The global community of heart rhythm specialists will unite in Paris from 12 to 14 April 2026 for EHRA 2026, the annual ...
The analysis supports making dapagliflozin part of standard inpatient HF pathways rather than postponing it until discharge.
Roxana Mehran, MD, FACC, today assumed the role of president of the American College of Cardiology. Mehran will serve a one-year term at the helm of the almost 60,000-member global cardiovascular ...
EU approves Bayer’s Kerendia for new indication in adult patients with heart failure with LVEF =40%: Berlin Tuesday, March 31, 2026, 14:00 Hrs [IST] Bayer, a global enterprise w ...
BioCardia believes these results provide additional evidence in support of benefit for the CardiAMP Cell Therapy for patients with ischemic heart failure of reduced ejection fraction. Reduced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results